Edwards Lifesciences officer plans sale of 544 shares

Edwards Lifesciences Corp (EW) is the issuer for a notice of proposed sale of securities filed for the account of officer Andrew M. Dahl under Rule 144.

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) is the issuer for a notice of proposed sale of securities filed for the account of officer Andrew M. Dahl under Rule 144. The filing covers up to 544 shares of common stock, held at Charles Schwab & Co., Inc., relating to a restricted stock lapse scheduled on 05/08/2026 and designated as Equity Compensation. The common stock is listed on the NYSE. The form indicates an outstanding share count of 576,400,000 common shares, which is a baseline figure for the issuer.

Key Figures

Shares proposed to be sold: 544 shares of common stock Aggregate market value: $49,534.00 Shares outstanding: 576,400,000 shares +2 more

5 metrics

Shares proposed to be sold 544 shares of common stock Maximum number of Edwards Lifesciences shares covered by this Rule 144 notice

Aggregate market value $49,534.00 Value shown for the 544 shares of Edwards Lifesciences common stock in the notice

Shares outstanding 576,400,000 shares Edwards Lifesciences common shares outstanding referenced in the filing

Restricted stock lapse date 05/08/2026 Date tied to the restricted stock lapse for the equity compensation shares

Broker Charles Schwab & Co., Inc. Broker listed as holding the 544 Edwards Lifesciences shares

Key Terms

Rule 144, Restricted Stock Lapse, Equity Compensation

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Lapse financial

"Common | 05/08/2026 | Restricted Stock Lapse | EDWARDS LIFESCIENCES CORPORATION"

Equity Compensation financial

"544 | 05/08/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

What does the Form 144 filing for EW disclose about Andrew M. Dahl’s planned sale?

The notice states that officer Andrew M. Dahl may sell up to 544 shares of Edwards Lifesciences Corp (EW) common stock under Rule 144. The shares are tied to a restricted stock lapse dated 05/08/2026 and classified as Equity Compensation.

How many Edwards Lifesciences (EW) shares are covered by this Form 144?

The filing covers a potential sale of up to 544 shares of Edwards Lifesciences common stock. These shares are associated with an equity compensation grant that lapses on 05/08/2026 and are held through Charles Schwab & Co., Inc..

What aggregate market value is shown for the EW shares in this Form 144?

The Form 144 lists an aggregate market value of $49,534.00 for the 544 shares of Edwards Lifesciences common stock covered by the notice. This figure reflects the value used in the Rule 144 filing.

What is the total number of Edwards Lifesciences (EW) shares outstanding referenced in the filing?

The notice references 576,400,000 shares of Edwards Lifesciences common stock as shares outstanding. This serves as a baseline figure for the issuer, distinct from the 544 shares that may be sold under the filing.

How were the EW shares in this Form 144 acquired by Andrew M. Dahl?

The shares are tied to a Restricted Stock Lapse on 05/08/2026 and are categorized as Equity Compensation. This indicates the shares arise from a compensation-related award from Edwards Lifesciences Corporation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:16 PM Accepted by SEC EDGAR 08/31/2026 - 04:15 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002022347
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Dahl Andrew M.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	544	49534.00	576400000	08/31/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/08/2026	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			544	05/08/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Andrew M. Dahl
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)